FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164922990> ?p ?o ?g. }

• W3164922990 endingPage "811" @default.
• W3164922990 startingPage "811.3" @default.
• W3164922990 abstract "Background: Obesity is highly overrepresented in psoriatic arthritis (PsA) and associated with increased disease activity. We have previously shown in 41 patients with PsA (Caspar criteria) and obesity (here body mass index BMI ≥33 kg/m 2 ) that weight loss treatment including Very Low Energy Liquid Diet (VLED) resulted in a median weight loss of 18.6% and concomitantly a significant improvement in CRP and disease activity in joints, entheses and skin at six months (M6) follow up. Objectives: To analyze serum biomarkers associated with inflammation, cartilage and bone metabolism before and after weight loss treatment in PsA patients compared with controls, without PsA or psoriasis, matched for age, sex and weight. Methods: The weight loss treatment included VLED (640 kcal/day) during 12 or 16 weeks (depending on baseline (BL) BMI <40 or ≥40 kg/m 2 ), followed by a structured reintroduction of an energy restricted diet. cs/bDMARDs were held unchanged from 3 months before BL until M6. The patients were assessed with 66/68 joints counts. Serum levels of vascular endothelial growth factor (VEGF), S100A8, S100A9, matrix metalloproteinases (MMP-3, 8 and 13), hepatocyte growth factor (HGF), B-cell activating factor (BAFF), Dickkopf (DKK)-1, sclerostin (SOST), soluble receptor activator of nuclear factor-kB ligand (RANKL), osteprotegerin (OPG) and aggrecan were measured at BL and M6 in PsA patients and controls with Magnetic Luminex Assays (R&D-systems) following the manufacturer’s instructions using a Bio-Plex 200 system (BioRad). Serum cartilage oligomeric matrix protein (COMP) (R&D-systems), carboxyterminal telopeptide of type-1 collagen (CTX-1) (Immunodiagnostics systems: IDS) and osteocalcin (IDS) were measured with enzyme-linked immunosorbent assay (ELISA). Results: Totally 41 PsA patients [age median 54 (IQR 48-62) yrs; 63 % women] and 39 controls [age 55 (46-60) yrs, 72 % women] were included. At M6 the weight-loss since BL was 18.7 (14.6-26.5) kg in the PsA patients and 22.6 (14.7-28.4) kg in the controls (p=0.546). Significant reductions in DAS28CRP [2.9 (2.1–3.7) vs. 2.4 (1.7–3.0)] and DAPSA [15.3(6.6-29.1) vs. 11.0 (2.8–17.6)] (p<0.001) were seen in the PsA patients. At BL serum levels of the biomarkers were not significantly different in patients vs. controls. After weight-loss significant reductions were seen in serum VEGF, S100A8, MMP-8, HGF, BAFF, COMP and DKK-1, whereas serum SOST and CTX-1 were significantly increased in both patients and controls (Table 1). The other biomarkers were not significantly changed. Conclusion: Weight loss in patients with PsA and controls was associated with lowered serum levels of several biomarkers related to inflammation and cartilage degradation, along with increased levels of biomarkers for bone turnover. Table 1. PsA (N=41 ) BL median (IQR ) PsA (N=41 ) M6 median (IQR ) PsA p-value Ctrl (N=39 ) BL median (IQR ) Ctrl (N=39 ) M6 median (IQR ) Ctrl p-value BMI (kg/m 2 ) 35.2 (34.1-38.1) 29.8 (26.6-31.5) <0.001 37.7 (36.7–41.5) 30.4 (27.9–33.2) <0.001 CRP (mg/L) 4 (2–8.5) 2 (1–6.5) 0.041 4 (2–6) 2 (1–4) <0.001 VEGF (pg/mL) 79.6 (55.9–113.5) 69.6 (53.1–105.3) 0.010 82.3 (48.0–125.9) 65.0 (42.2-85.5) <0.001 S100A8 (pg/mL) 75.5 (48.0–99.5) 63.3 (42.8–93.6) 0.021 71.8 (40.5–101.0) 63.3 (40.3-85.7) 0.006 MMP-8 (pg/mL) 9975.4 (6811.8–14154.8) 9202.6 (5767.1–12049.6) 0.017 7494.7 (4805.2-12616.9) 7218.3 (3466.0-9785.3) 0.112 HGF (pg/mL) 327.9 (250.3–413.6) 271.3 (206.9–331.0) <0.001 307.9 (239.1–348.3) 239.8 (200.3-276.0) <0.001 BAFF (pg/mL) 794.4 (716.4–868.2) 674.6 (613.2–790.5) <0.001 760.8 (664.1–827.3) 678.1 (603.7–719.8) <0.001 COMP (pg/mL) 266.1 (209.8–366.0) 217.0 (156.0–272.0) 0.008 293.6 (185.2–340.5) 221.6 (163.5-300.0) 0.018 Dkk-1 (pg/mL) 3608.4 (3055.0–4401.3) 3382.6 (2802.5–4218.2) 0.002 3635.8 (3212.8-4380.6) 3480.4 (2948.9–4087.3) 0.007 SOST (pg/mL) 52.9 (32.5–65.4) 60.3 (37.2–85.6) 0.014 50.0 (30.8–79.3) 61.3(35.7–81.4) 0.019 CTX-1 (ng/mL) 0.27 (0.20–0.39) 0.51 (0.35–0.64) <0.001 0.23 (0.16–0.34) 0.50(0.30–0.61) <0.001 Disclosure of Interests: None declared." @default.
• W3164922990 created "2021-06-07" @default.
• W3164922990 creator A5009715320 @default.
• W3164922990 creator A5025069589 @default.
• W3164922990 creator A5034536128 @default.
• W3164922990 creator A5042372370 @default.
• W3164922990 creator A5061198575 @default.
• W3164922990 creator A5063157827 @default.
• W3164922990 creator A5078478446 @default.
• W3164922990 creator A5090931547 @default.
• W3164922990 date "2021-05-19" @default.
• W3164922990 modified "2023-09-25" @default.
• W3164922990 title "POS1064 SERUM BIOMARKERS BEFORE AND AFTER A SIX MONTHS STRUCTURED WEIGHT LOSS INTERVENTION IN PATIENTS WITH PSORIATIC ARTHRITIS AND OBESITY COMPARED WITH CONTROLS" @default.
• W3164922990 doi "https://doi.org/10.1136/annrheumdis-2021-eular.999" @default.
• W3164922990 hasPublicationYear "2021" @default.
• W3164922990 type Work @default.
• W3164922990 sameAs 3164922990 @default.
• W3164922990 citedByCount "1" @default.
• W3164922990 countsByYear W31649229902022 @default.
• W3164922990 crossrefType "journal-article" @default.
• W3164922990 hasAuthorship W3164922990A5009715320 @default.
• W3164922990 hasAuthorship W3164922990A5025069589 @default.
• W3164922990 hasAuthorship W3164922990A5034536128 @default.
• W3164922990 hasAuthorship W3164922990A5042372370 @default.
• W3164922990 hasAuthorship W3164922990A5061198575 @default.
• W3164922990 hasAuthorship W3164922990A5063157827 @default.
• W3164922990 hasAuthorship W3164922990A5078478446 @default.
• W3164922990 hasAuthorship W3164922990A5090931547 @default.
• W3164922990 hasBestOaLocation W31649229901 @default.
• W3164922990 hasConcept C126322002 @default.
• W3164922990 hasConcept C134018914 @default.
• W3164922990 hasConcept C167734588 @default.
• W3164922990 hasConcept C170493617 @default.
• W3164922990 hasConcept C2776260265 @default.
• W3164922990 hasConcept C2777025900 @default.
• W3164922990 hasConcept C2777077863 @default.
• W3164922990 hasConcept C2779428903 @default.
• W3164922990 hasConcept C2780221984 @default.
• W3164922990 hasConcept C2780426850 @default.
• W3164922990 hasConcept C511355011 @default.
• W3164922990 hasConcept C544821477 @default.
• W3164922990 hasConcept C71924100 @default.
• W3164922990 hasConcept C88045685 @default.
• W3164922990 hasConcept C90924648 @default.
• W3164922990 hasConceptScore W3164922990C126322002 @default.
• W3164922990 hasConceptScore W3164922990C134018914 @default.
• W3164922990 hasConceptScore W3164922990C167734588 @default.
• W3164922990 hasConceptScore W3164922990C170493617 @default.
• W3164922990 hasConceptScore W3164922990C2776260265 @default.
• W3164922990 hasConceptScore W3164922990C2777025900 @default.
• W3164922990 hasConceptScore W3164922990C2777077863 @default.
• W3164922990 hasConceptScore W3164922990C2779428903 @default.
• W3164922990 hasConceptScore W3164922990C2780221984 @default.
• W3164922990 hasConceptScore W3164922990C2780426850 @default.
• W3164922990 hasConceptScore W3164922990C511355011 @default.
• W3164922990 hasConceptScore W3164922990C544821477 @default.
• W3164922990 hasConceptScore W3164922990C71924100 @default.
• W3164922990 hasConceptScore W3164922990C88045685 @default.
• W3164922990 hasConceptScore W3164922990C90924648 @default.
• W3164922990 hasIssue "Suppl 1" @default.
• W3164922990 hasLocation W31649229901 @default.
• W3164922990 hasOpenAccess W3164922990 @default.
• W3164922990 hasPrimaryLocation W31649229901 @default.
• W3164922990 hasRelatedWork W1976715250 @default.
• W3164922990 hasRelatedWork W2026854426 @default.
• W3164922990 hasRelatedWork W2029202516 @default.
• W3164922990 hasRelatedWork W2042509724 @default.
• W3164922990 hasRelatedWork W2051222892 @default.
• W3164922990 hasRelatedWork W2096579567 @default.
• W3164922990 hasRelatedWork W2110901553 @default.
• W3164922990 hasRelatedWork W2124998345 @default.
• W3164922990 hasRelatedWork W2125983743 @default.
• W3164922990 hasRelatedWork W2326832210 @default.
• W3164922990 hasVolume "80" @default.
• W3164922990 isParatext "false" @default.
• W3164922990 isRetracted "false" @default.
• W3164922990 magId "3164922990" @default.
• W3164922990 workType "article" @default.